The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma

AIDS

Volumn 23, Issue 13, 2009, Pages 1701-1706

  Bower, Mark ^a   Weir, Justin ^a   Francis, Nicholas ^a   Newsom Davis, Tom ^a   Powles, Sam ^a   Crook, Tim ^a   Boffito, Marta ^a   Gazzard, Brian ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HAART; HIV; Kaposi's sarcoma

Indexed keywords

ANTHRACYCLINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SARCOMA, KAPOSI; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 69449098026     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832d080d     Document Type: Article

References (44)

1. Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men: New York City and California. MMWR Morbid Mortal Wkly Rep 1981; 30:250-254
2. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96:693-700. (Pubitemid 12029334)
3. Center for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36 (Suppl 1):1S-15S.
4. Nasti G, Errante D, Santarossa S, Vaccher E, Tirelli U. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf 1999; 20:403-425. (Pubitemid 29231656)
5. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001; 19:3848-3851. (Pubitemid 32880063)
6. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999; 21 (Suppl 1):S34-S41. (Pubitemid 29357647)
7. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
8. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22. (Pubitemid 36951678)
9. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
10. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:17-22. (Pubitemid 36951678)
11. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13:2105-2111. (Pubitemid 29509588)
12. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367:1495-1502.
13. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, Detels R. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98:916-922. (Pubitemid 34286691)
14. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009; 20:775-779.
15. Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002; 30:257-258. (Pubitemid 34664423)
16. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390. (Pubitemid 35397090)
17. Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35:1809-1815. (Pubitemid 29512313)
18. + T cell recovery. Infection 2005; 33:140-147.
19. Esdaile B, Davis M, Portsmouth S, Sarker D, Nelson M, Gazzard B, Bower M. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. AIDS 2002; 16:2344-2347. (Pubitemid 35449025)
20. Nunez M, Saballs P, ValenciaME, Santos J, Ferrer E, Santos I, et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001; 2:429-437. (Pubitemid 32952311)
21. Krown SE, Metroka C, Wernz JC, AIDS Clinical Trials Group Oncology Committee. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7:1201-1207.
22. Krown SE, Testa MA, Huang J, AIDS Clinical Trials Group Oncology Committee. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. J Clin Oncol 1997; 15:3085-3092. (Pubitemid 27413610)
23. Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9:336-388.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
25. Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 1977; 35:1-39. (Pubitemid 8018922)
26. Ledergerber B, Telenti A, Egger M, Swiss HIV Cohort Study. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. BMJ 1999; 319:23-24.
27. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. (Pubitemid 351705208)
28. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
29. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804.
30. Chan J, Kravcik S, Angel JB. Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J Acquir Immune Defic Syndr 1999; 22:209-210.
31. Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008; 358:535-536; author reply 536.
32. Stebbing J, Powles T, Bower M. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. AIDS 2008; 22:551-552. (Pubitemid 351317307)
33. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352-1353. (Pubitemid 47481472)
34. Francis ND, Parkin JM, Weber J, Boylston AW. Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). J Clin Pathol 1986; 39:469-474. (Pubitemid 16071249)
35. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3:31.
36. Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthe H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 2000; 14:987-993.
37. Dupin N, Rubin De Cervens V, Gorin I, Calvez V, Pessis E, Grandadam M, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Dermatol 1999; 140:875-881. (Pubitemid 29238459)
38. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12:45-49. (Pubitemid 28190688)
39. Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21:1245-1252.
40. Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008; 22:937-945. (Pubitemid 351652244)
41. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-232. (Pubitemid 34250099)
42. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard BG. HAART prolongs time to treatment failure (TTF) in Kaposi's sarcoma. J Acquir Immune Defic Syndr 1999; 21:A24.
43. Martinez V, Caumes E, Gambotti L, Ittah H,Morini JP, Deleuze J, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000-1006.
44. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399-402.